Janux Therapeutics (JANX) Stock Forecast & Price Target $14.52 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$14.51 -0.01 (-0.07%) As of 05/22/2026 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Janux Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 15 Analyst RatingsSell2Hold3Buy10 Based on 15 Wall Street analysts who have issued ratings for Janux Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a sell rating, 3 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for JANX. Consensus Price Target $45.85215.74% Upside According to the 15 analysts' twelve-month price targets for Janux Therapeutics, the average price target is $45.85. The highest price target for JANX is $100.00, while the lowest price target for JANX is $14.00. The average price target represents a forecasted upside of 215.74% from the current price of $14.52. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for JANX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JANX Analyst Ratings Over TimeTypeCurrent Forecast5/25/25 to 5/25/261 Month Ago4/25/25 to 4/25/263 Months Ago2/24/25 to 2/24/261 Year Ago5/25/24 to 5/25/25Strong Buy1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy9 Buy rating(s)9 Buy rating(s)11 Buy rating(s)8 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)3 Hold rating(s)1 Hold rating(s)Sell2 Sell rating(s)2 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$45.85$51.73$60.08$95.25Forecasted Upside215.74% Upside244.62% Upside340.17% Upside277.68% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyBuy JANX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History JANX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Janux Therapeutics Stock vs. The CompetitionTypeJanux TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 2.60 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside215.74% Upside1,714.95% Upside15.09% UpsideNews Sentiment RatingNeutral NewsSee Recent JANX NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/11/2026 Evercore3 of 5 stars Set Target$22.00+51.57%5/8/2026 Piper Sandler2 of 5 starsKelsey GoodwinNot RatedLower TargetOverweight$30.00 ➝ $26.00+83.84%5/8/2026 Wedbush5 of 5 starsRobert Driscoll5 of 5 starsLower TargetOutperform$45.00 ➝ $36.00+151.84%5/8/2026 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrad CaninoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$68.00 ➝ $58.00+298.90%5/4/2026 Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy4/28/2026 JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoris PeakerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$50.00 ➝ $28.00+94.92%4/22/2026 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeSell (E+) ➝ Sell (D-)4/20/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEtzer DaroutSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOverweight ➝ Underweight$29.00 ➝ $14.00-11.50%4/15/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid DaiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral$57.00 ➝ $15.00-1.57%2/27/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJosh SchimmerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$150.00 ➝ $100.00+639.97% Get the Latest News and Ratings for JANX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/20/2026 Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold12/2/2025 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingStephen WilleySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$46.00 ➝ $38.00+11.80%12/2/2025 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSwayampakula RamakanthSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$70.00 ➝ $45.00+32.39%12/2/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGeoff MeachamSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$58.00 ➝ $49.00+44.16%11/18/2025 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKalpit PatelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoveragePeer Perform7/11/2025 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSean McCutcheonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$65.00+153.81%2/28/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGeorge FarmerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetSector Perform$62.00 ➝ $41.00+24.66%1/10/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform12/27/2024 Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingO. MccammonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy12/3/2024 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOutperform$79.00 ➝ $91.00+46.09%12/3/2024 BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$82.00 ➝ $100.00+148.88%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:06 AM ET. JANX Forecast - Frequently Asked Questions What is Janux Therapeutics' forecast for 2026? According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Janux Therapeutics is $45.85, with a high forecast of $100.00 and a low forecast of $14.00. Should I buy or sell Janux Therapeutics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JANX shares. Does Janux Therapeutics's stock price have much upside? According to analysts, Janux Therapeutics's stock has a predicted upside of 215.74% based on their 12-month stock forecasts. Has Janux Therapeutics been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Janux Therapeutics's stock had 2 upgrades and 2 downgrades by analysts. What analysts cover Janux Therapeutics? Janux Therapeutics has been rated by research analysts at Barclays, Cantor Fitzgerald, Evercore, Guggenheim, JonesTrading, Piper Sandler, Truist Financial, UBS Group, Wedbush, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Janux Therapeutics more than its competitors? Analysts like Janux Therapeutics more than other "medical" companies. The consensus rating for Janux Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how JANX compares to other companies. Stock Forecasts and Research Tools Related Companies Erasca Stock Forecast Twist Bioscience Stock Forecast Arcus Biosciences Stock Forecast Tango Therapeutics Stock Forecast Denali Therapeutics Stock Forecast Alumis Stock Forecast Beam Therapeutics Stock Forecast Dyne Therapeutics Stock Forecast Structure Therapeutics Stock Forecast Tarsus Pharmaceuticals Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Janux Therapeutics RecommendationsEvercoreGuggenheimWedbushPiper SandlerTruist FinancialJonesTradingWeiss RatingsBarclaysUBS GroupWall Street ZenCantor FitzgeraldClear StrStifel NicolausHC WainwrightBank of America This page (NASDAQ:JANX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
